A. Mumford
A. Mumford publishes mostly in Economics and Econometrics, Public Health, Environmental and Occupational Health and Physiology, on topics such as Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical Economics and Policy and Biomedical Ethics and Regulation.
- World rank
- #5,318,516 of 7,710,434 ranked researchers
- Rank in United Kingdom
- #313,905 of 367,258
- Works
- 23
- Citations
- 7
- Citations per work
- 0.3
What does A. Mumford research?
A. Mumford's work is mostly in Economics, Econometrics and Finance (36%), Medicine (23%), Biochemistry, Genetics and Molecular Biology (4%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Social Sciences836.5%
- Everything else832.8%
- Health Sciences626.9%
- Medicine523.1%
- Health Professions13.8%
- Life Sciences13.8%
- 1Economics and Econometrics36% of their works
- 2Public Health, Environmental and Occupational Health8% of their works
- 3Physiology8% of their works
- 4Pediatrics, Perinatology and Child Health8% of their works
- 5General Health Professions4% of their works
- 6Genetics4% of their works
Research topics
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Biomedical Ethics and Regulation
- Biotechnology and Related Fields
- Pharmaceutical studies and practices
- Genomics and Rare Diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Entomopathogenic Microorganisms in Pest Control
Which keywords describe A. Mumford's research?
The keywords of their largest research topics: Cost-effectiveness Analysis, Quality of Life, Clinical Trials, Drug Development Costs, Generic Drugs, Global Collaboration, Health Biotechnology and Regulatory Challenges.
- Biological Control
- Myelofibrosis
- Genetic Variants
- Off-Label Drug Use
- Regulatory Challenges
- Global Collaboration
- Drug Development Costs
- Quality of Life
- Cost-effectiveness Analysis
- Clinical Trials
- Generic Drugs
- Health Biotechnology
- Stem Cell Regulation
- Pediatric Pharmacokinetics
- JAK2 Mutation
- Sequence Interpretation
- Entomopathogenic Fungi
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 17 words, with their numbers
- Cost-effectiveness Analysis131 topic
- Quality of Life131 topic
- Clinical Trials72 topics
- Drug Development Costs61 topic
- Generic Drugs61 topic
- Global Collaboration41 topic
- Health Biotechnology41 topic
- Regulatory Challenges41 topic
- Stem Cell Regulation41 topic
- Off-Label Drug Use31 topic
- Pediatric Pharmacokinetics31 topic
- Genetic Variants21 topic
- JAK2 Mutation21 topic
- Myelofibrosis21 topic
- Sequence Interpretation21 topic
- Biological Control11 topic
- Entomopathogenic Fungi11 topic
Where does A. Mumford work?
A. Mumford's main affiliation in the publication record is 21c Consultancy (United Kingdom), United Kingdom.
How many publications and citations does A. Mumford have?
OpenAlex counts 23 works and 7 citations for A. Mumford, an h-index of 2, ranking #5,318,516 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about A. Mumford. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.